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JACC WHITE PAPER JACC WHITE PAPERFrailty in Cardiovascular Care 747Jonathan Aﬁlalo, Karen P. Alexander, Michael J. Mack, Mathew S. Maurer, Philip Green,
Larry A. Allen, Jeffrey J. Popma, Luigi Ferrucci, Daniel E. Forman
Due to aging and the increasingly complex nature of cardiovascular patients, frailty has
become an important issue in cardiovascular medicine. Epidemiological studies have
consistently demonstrated that frailty carries a relative risk of >2 for mortality and morbidity
across a spectrum of stable cardiovascular disease, acute coronary syndrome, heart failure, and
surgical and transcatheter interventions. In this state-of-the-art paper, Aﬁlalo and colleagues:
1) summarize the existing body of evidence for frailty in patients with cardiovascular disease;
2) offer a perspective on integrating frailty into current clinical practice; and 3) point out the
knowledge gaps for future research.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYDirect Flow Medical Aortic Valve 763Joachim Schofer, Antonio Colombo, Silvio Klugmann, Jean Fajadet, Federico DeMarco, Didier Tchétché,
Francesco Maisano, Giuseppe Bruschi, Azeem Latib, Klaudija Bijuklic, Neil Weissman, Reginald Low,
Martyn Thomas, Christopher Young, Simon Redwood, Michael Mullen, John Yap, Eberhard Grube,
Georg Nickenig, Jan-Malte Sinning, Karl Eugen Hauptmann, Ivar Friedrich, Michael Lauterbach,
Michael Schmoeckel, Charles Davidson, Thierry Lefevre
The Direct Flow Medical (DFM) transcatheter aortic valve system (Santa Rosa, California) is
a nonmetallic design with a pressurized support structure, which allows precise positioning,
retrieval, and assessment of value performance prior to permanent implantation. The study
reports on the results of a multicenter, nonrandomized evaluation of the DFM system for the
treatment of severe aortic stenosis. The results reveal that there was 99% freedom from
all-cause mortality at 30 days. The Valve Academic Research Consortium–deﬁned 30-day
combined freedom from patient safety event rate was 91%, and overall device success was
93%. Post-implantation echocardiography demonstrated mild or no aortic insufﬁciency in
99%. The present study demonstrates the safety and efﬁcacy of the DFM system in high-risk
surgical patients with severe aortic stenosis.(continued on page A-36)
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José L. Ferreiro, Deepak L. Bhatt, Masafumi Ueno, Deborah Bauer, Dominick J. Angiolillo
Smoking enhances clopidogrel-induced platelet inhibition, which may explain the higher
relative beneﬁt among smokers in trials evaluating dual antiplatelet therapy. This study
investigated whether smoking impacts clinical outcome in patients with atherosclerotic
vascular disease and taking a single antiplatelet agent. Post-hoc analysis of the CAPRIE
(Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events) trial was completed.
Clopidogrel was associated with a reduction in ischemic events among current smokers (8.3%
vs. 10.8%, hazard ratio: 0.76), whereas no beneﬁt over aspirin was seen in the combined
group of ex-smokers/patients who never smoked. Among current smokers, clopidogrel also
reduced myocardial infarction, vascular death, and death from any cause compared with
aspirin. Ferreiro and colleagues conclude that, in a post-hoc analysis of the CAPRIE
population, current smokers appeared to have enhanced beneﬁt with clopidogrel therapy for
secondary prevention compared with aspirin.HEART FAILUREWorldwide Obesity Paradox in Heart Failure 778Ravi Shah, Etienne Gayat, James L. Januzzi, Jr, Naoki Sato, Alain Cohen-Solal,
Salvatore diSomma, Enrique Fairman, Veli-Pekka Harjola, Shiro Ishihara, Johan Lassus,
Aldo Maggioni, Marco Metra, Christian Mueller, Thomas Mueller, Jiri Parenica,
Domingo Pascual-Figal, William Frank Peacock, Jindrich Spinar, Roland van Kimmenade,
Alexandre Mebazaa, for the GREAT (Global Research on Acute Conditions Team) Network
Obesity is associated with incident heart failure (HF) but is paradoxically associated with
better prognosis during chronic HF. This study attempts to deﬁne the relationship between
body mass index (BMI) and mortality in HF worldwide. The results reveal that, despite
worldwide heterogeneity in clinical features across obesity categories, a higher BMI remained
associated with a decrease in 30-day and 1-year mortality (11% decrease at 30 days; 9%
decreased at 1 year per 5 kg/m2), after adjustment for clinical risk. The BMI obtained at
index admission provided effective 1-year risk reclassiﬁcation beyond current markers of
clinical risk (net reclassiﬁcation index 0.119). The “protective” association of BMI with
mortality was conﬁned to older patients (age >75 years: hazard ratio [HR]: 0.82) and those
with decreased cardiac function (ejection fraction <50%, HR: 0.85), without diabetes (HR:
0.86), and with de novo HF (HR: 0.89). The study concludes that a lower BMI is associated
with age, disease severity, and a higher risk of death in acute decompensated heart failure.
The obesity paradox is conﬁned to older individuals and those with decreased cardiac
function, less cardiometabolic illness, and recent-onset HF, suggesting that aging, HF
severity/chronicity, and metabolism may explain the obesity paradox.
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Dodson and colleagues developed and validated a risk model to predict in-hospital adverse
events after implantable cardioverter-deﬁbrillator (ICD) implantation. Data from the
National Cardiovascular Data Registry (NCDR) ICD registry were used. Overall, 4,388
(1.8%) patients experienced at least 1 in-hospital complication or death. Thirteen factors were
independently associated with an increased risk of adverse outcomes. The risk score
characterized patients into low- and high-risk subgroups for adverse events (10 points,
0.3%; 30 points, 4.2%). The authors have developed a simple model that predicts risk for
in-hospital adverse events among patients undergoing ICD placement. This can be used for
shared decision-making and to benchmark hospital performance.
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Christopher A. Miller, Jaydeep Sarma, Josephine H. Naish, Nizar Yonan, Simon G. Williams,
Steven M. Shaw, David Clark, Keith Pearce, Martin Stout, Rahul Potluri, Alex Borg, Glyn Coutts,
Saqib Chowdhary, Gerry P. McCann, Geoffrey J. M. Parker, Simon G. Ray, Matthias Schmitt
Miller and colleagues investigated the diagnostic performance of multiparametric
cardiovascular magnetic resonance (CMR) for detecting cardiac allograft vasculopathy
(CAV). A total of 48 transplant recipients (single center) who were referred for surveillance
angiography prospectively underwent coronary angiography followed by coronary
intravascular ultrasound, fractional ﬂow reserve, and index of microcirculatory resistance.
Patients also underwent multiparametric CMR, including assessment of regional and global
ventricular function, absolute myocardial blood ﬂow quantiﬁcation, and myocardial tissue
characterization. Results showed that CMR myocardial perfusion reserve was the only
independent predictor of both epicardial and microvascular disease. CMR myocardial
perfusion reserve signiﬁcantly outperformed angiography for detecting moderate CAV and
severe CAV. The study concludes that CAV, including epicardial and microvascular
components, can be detected more accurately using noninvasive CMR-based absolute
myocardial blood ﬂow assessment than with invasive coronary angiography.(continued on page A-38)
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Bonnie Ky, Mary Putt, Heloisa Sawaya, Benjamin French, James L. Januzzi, Jr, Igal A. Sebag,
Juan Carlos Plana, Victor Cohen, Jose Banchs, Joseph R. Carver, Susan E. Wiegers,
Randolph P. Martin, Michael H. Picard, Robert E. Gerszten, Elkan F. Halpern, Jonathan Passeri,
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The object of this study was to determine the potential utility of biomarkers for the early
identiﬁcation of breast cancer patients at risk of cardiac dysfunction. Eight biomarkers were
measured in a multicenter cohort of 78 breast cancer patients undergoing doxorubicin and
trastuzumab therapy. Cardiotoxicity, as deﬁned by the Cardiac Review and Evaluation
Committee criteria, was assessed. Results revealed that a greater risk of cardiotoxicity was
associated with an interval change in ultrasensitive troponin I (TnI) (hazard ratio [HR]: 1.38
per SD), in myeloperoxidase (MPO) (HR: 1.34 per SD), and in models combining both
markers. The risk of cardiotoxicity was 46.5% in patients with the largest changes in both
markers. Ky and colleagues conclude that an early increase in TnI and MPO offers additive
information about cardiotoxicity risk in patients undergoing doxorubicin and trastuzumab
therapy.
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Hiroshi Matsuura, Minoru Horie
The purpose of this study was to explore the molecular mechanism underlying the
adrenergic-induced QT prolongation associated with KCNQ1 mutations. Recently, a
heterozygous missense KCNQ1 mutation, G269S, has been identiﬁed in 11 patients.
Wild-type (WT) KCNQ1 and/or KCNQ1-G269S (G269S) were expressed in mammalian
cells with KCNE1 and studied. The coexpression of WT-KCNQ1 with varying amounts of
G269S decreased the slow component of delayed rectiﬁer K+ current (IKs), shifted the I-V
relation of IKs to more positive potentials, and accelerated the IKs deactivation rates in a
concentration-dependent manner. In addition, the coexpression of G269S and WT blunted
the activation of IKs in response to isoproterenol or protein kinase (PKA) stimulation. This
study shows that G269S modestly affected IKs in control conditions, but almost completely
blunted IKs responsiveness in conditions that simulate or mimic PKA phosphorylation of
KCNQ1. This insensitivity to PKA stimulation may explain why patients with a G269S
mutation showed an excessive prolongation of QT intervals on exercise.
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